Recognition and Therapeutic Options for Malignancy of the Cervix and Uterus

被引:2
作者
Burton, Elizabeth R. [1 ]
Sorosky, Joel I. [2 ]
机构
[1] Thomas Jefferson Univ, Sidney Kimmel Med Coll,Jefferson Hlth, Div Gynecol Oncol,Dept Obstet & Gynecol, Hanjani Inst Gynecol Oncol,Abington Hosp, 1200 Old York Rd,1 Weidner Bldg, Abington, PA 19001 USA
[2] Thomas Jefferson Univ, Dept Obstet & Gynecol, Hanjani Inst Gynecol Oncol,Jefferson Hlth, Abington Hosp,Sidney Kimmel Med Coll, 1200 Old York Rd,1 Weidner Bldg, Abington, PA 19001 USA
关键词
Cervical and endometrial cancer; Prevention; Risk factors; Genetics; Screening; Treatment; ENDOMETRIAL; CANCER; SURVEILLANCE; RECURRENCE; CYTOLOGY;
D O I
10.1016/j.ogc.2017.02.009
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
An update on the current epidemiology and a review of the risk factors of cervical and endometrial cancers are discussed. Cervical cancer prevention with a focus on human papillomavirus vaccination and cervical cancer screening is reviewed, emphasizing the new focus of less frequent intervention in an effort to maintain high rates of early detection of disease while decreasing unnecessary and anxiety-provoking colposcopies, biopsies, and excisional procedures. The replacement of traditional endometrial hyperplasia terminology with more relevant clinical categories, with an emphasis on the introduction of endometrial intraepithelial neoplasia, is presented. Fertility-sparing options in the management of early cervical and endometrial cancers are reviewed.
引用
收藏
页码:195 / +
页数:14
相关论文
共 16 条
[1]  
American College of Obstetricians and Gynecologists, 2013, Obstet Gynecol, V122, P1338, DOI 10.1097/01.AOG.0000438960.31355.9e
[2]  
[Anonymous], 2015, Obstet Gynecol, V126, pe38, DOI 10.1097/AOG.0000000000001052
[3]  
[Anonymous], 2016, Obstet Gynecol, V127, pe1, DOI 10.1097/AOG.0000000000001263
[4]  
[Anonymous], 2015, Obstet Gynecol, V125, P1272, DOI 10.1097/01.AOG.0000465189.50026.20
[5]  
[Anonymous], 2014, Obstet Gynecol, V124, P1042, DOI 10.1097/01.AOG.0000456325.50739.72
[6]  
[Anonymous], IN ABIM FDN
[7]   POSTSURGICAL SURVEILLANCE OF PATIENTS WITH FIGO STAGE I/II ENDOMETRIAL ADENOCARCINOMA [J].
BERCHUCK, A ;
ANSPACH, C ;
EVANS, AC ;
SOPER, JT ;
RODRIGUEZ, GC ;
DODGE, R ;
ROBBOY, S ;
CLARKEPEARSON, DL .
GYNECOLOGIC ONCOLOGY, 1995, 59 (01) :20-24
[8]   Clinical Utility of Positron Emission Tomography/Computed Tomography in the Evaluation of Suspected Recurrent Ovarian Cancer in the Setting of Normal CA-125 Levels [J].
Bhosale, Priya ;
Peungjesada, Silanath ;
Wei, Wei ;
Levenback, Charles F. ;
Schmeler, Kathleen ;
Rohren, Eric ;
Macapinlac, Homer A. ;
Iyer, Revathy B. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (06) :936-944
[9]   Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance [J].
Bristow, Robert E. ;
Purinton, Scott C. ;
Santillan, Antonio ;
Diaz-Montes, Teresa P. ;
Gardner, Ginger J. ;
Giuntoli, Robert L., II .
GYNECOLOGIC ONCOLOGY, 2006, 103 (02) :709-713
[10]   The role of PET scanning in the detection of recurrent cervical cancer [J].
Havrilesky, LJ ;
Wong, TZ ;
Secord, AA ;
Berchuck, A ;
Clarke-Pearson, DL ;
Jones, EL .
GYNECOLOGIC ONCOLOGY, 2003, 90 (01) :186-190